240 related articles for article (PubMed ID: 33730314)
21. Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients.
Zhou X; Zhou X; Shi H; Lai J; Wang Q; Li Y; Chen K; Li Q; Zhou Q; Cao X; Chen B; Xiao J
BMC Ophthalmol; 2020 May; 20(1):189. PubMed ID: 32397978
[TBL] [Abstract][Full Text] [Related]
22. Use of intravitreal rituximab and methotrexate in vitreoretinal lymphoma.
Rahhal-Ortuño M; Udaondo-Mirete P; Fernández-Santodomingo AS; Díaz-Llopis M
Eur J Ophthalmol; 2022 Jan; 32(1):NP199-NP202. PubMed ID: 32985253
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal Analysis of Ocular Manifestation and Interleukin During Intravitreal Treatment of Vitreoretinal Lymphoma With Methotrexate.
Gu J; Jiang T; Liu S; Chen X; Wang Z; Zhang P; Wang L; Jiang R; Huang X; Xu G; Chang Q
Am J Ophthalmol; 2023 Jul; 251():189-196. PubMed ID: 36963600
[TBL] [Abstract][Full Text] [Related]
24. Intraocular T-cell Lymphoma: Clinical Presentation, Diagnosis, Treatment, and Outcome.
Chaput F; Amer R; Baglivo E; Touitou V; Kozyreff A; Bron D; Bodaghi B; LeHoang P; Bergstrom C; Grossniklaus HE; Chan CC; Pe'er J; Caspers LE
Ocul Immunol Inflamm; 2017 Oct; 25(5):639-648. PubMed ID: 27002464
[TBL] [Abstract][Full Text] [Related]
25. Acute Sterile Endophthalmitis Following Intravitreal Rituximab Injection in Primary Vitreoretinal Lymphoma: Case Series.
Guneri Beser B; Demirci H
Ocul Immunol Inflamm; 2023 Mar; ():1-6. PubMed ID: 36952513
[TBL] [Abstract][Full Text] [Related]
26. CLINICAL FEATURES, DIAGNOSTIC SIGNIFICANCE, AND PROGNOSIS OF VITREORETINAL LYMPHOMA IN YOUNG PATIENTS.
Liu S; Gu J; Zhang T; Ping B; Zhou M; Huang X; Jiang R; Xu G; Chang Q
Retina; 2021 Dec; 41(12):2596-2604. PubMed ID: 34173362
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of intravitreal methotrexate to salvage eyes with relapsed primary intraocular lymphoma.
Mohammad M; Andrews RM; Plowman PN; Hay G; Arora AK; Cohen VML; Sagoo MS
Br J Ophthalmol; 2022 Jan; 106(1):135-140. PubMed ID: 33087316
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.
Frenkel S; Hendler K; Siegal T; Shalom E; Pe'er J
Br J Ophthalmol; 2008 Mar; 92(3):383-8. PubMed ID: 18303160
[TBL] [Abstract][Full Text] [Related]
29. Presentation, Diagnostic Testing and Initial Treatment of Vitreoretinal Lymphoma.
International Vitreoretinal B-Cell Lymphoma Registry Investigator Group
Ophthalmol Retina; 2024 Jan; 8(1):72-80. PubMed ID: 37648063
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal injection of melphalan for intraocular retinoblastoma.
Suzuki S; Aihara Y; Fujiwara M; Sano S; Kaneko A
Jpn J Ophthalmol; 2015 May; 59(3):164-72. PubMed ID: 25808017
[TBL] [Abstract][Full Text] [Related]
31. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma.
Salomão DR; Pulido JS; Johnston PB; Canal-Fontcuberta I; Feldman AL
JAMA Ophthalmol; 2013 Sep; 131(9):1151-8. PubMed ID: 23744124
[TBL] [Abstract][Full Text] [Related]
32. AN UNUSUAL CASE OF PRIMARY VITREORETINAL LYMPHOMA: A TRANSFORMED LYMPHOMA.
Ustaoglu M; Patel R; Wang W; Shah S; Barr C
Retin Cases Brief Rep; 2024 Mar; 18(2):181-183. PubMed ID: 36730965
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.
Shields CL; Manjandavida FP; Arepalli S; Kaliki S; Lally SE; Shields JA
JAMA Ophthalmol; 2014 Mar; 132(3):319-25. PubMed ID: 24407202
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Complications of Intravitreal Rituximab Injection for Treating Primary Vitreoretinal Lymphoma.
Hashida N; Ohguro N; Nishida K
Transl Vis Sci Technol; 2012; 1(3):1. PubMed ID: 24049708
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic vitrectomy for vitreal recurrence of intraocular lymphoma resistant to intravitreal methotrexate post systemic chemotherapy.
Venkatesh P; Gogia V; Khanduja S; Gupta S; Kumar L; Garg S
J Cancer Res Ther; 2015; 11(3):668. PubMed ID: 26458712
[TBL] [Abstract][Full Text] [Related]
36. Aqueous Humor-Derived MYD88 L265P Mutation Analysis in Vitreoretinal Lymphoma: A Potential Less Invasive Method for Diagnosis and Treatment Response Assessment.
Demirci H; Rao RC; Elner VM; Demirci FY; Axenov L; Betz B; Behdad A; Brown N
Ophthalmol Retina; 2023 Feb; 7(2):189-195. PubMed ID: 35952929
[TBL] [Abstract][Full Text] [Related]
37. Clinical Features and Treatment Outcomes of Vitreoretinal Lymphoma according to Its Association with CNS Lymphoma.
Cho BJ; Kim DY; Park UC; Lee JY; Yoon YH; Yu HG
Ocul Immunol Inflamm; 2018; 26(3):365-371. PubMed ID: 29394118
[TBL] [Abstract][Full Text] [Related]
38. Primary Vitreoretinal Lymphoma in HIV Infection.
Steffen J; Coupland SE; Smith JR
Ocul Immunol Inflamm; 2021 Apr; 29(3):621-627. PubMed ID: 32453669
[No Abstract] [Full Text] [Related]
39. Potential Diagnosis of Vitreoretinal Lymphoma by Detection of MYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction.
Hiemcke-Jiwa LS; Ten Dam-van Loon NH; Leguit RJ; Nierkens S; Ossewaarde-van Norel J; de Boer JH; Roholl FF; de Weger RA; Huibers MMH; de Groot-Mijnes JDF; Kuiper JJW
JAMA Ophthalmol; 2018 Oct; 136(10):1098-1104. PubMed ID: 30027272
[TBL] [Abstract][Full Text] [Related]
40. Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy.
Gozzi F; Aldigeri R; Mastrofilippo V; De Simone L; Bolletta E; Marzano J; Iannetta D; Coassin M; Ilariucci F; Ferrari A; Luminari S; Merli F; Croci S; Zerbini A; Farnetti E; Nicoli D; Valli R; Tamagnini I; Cavazza A; Salvarani C; Fontana L; Cimino L
Ocul Immunol Inflamm; 2022; 30(7-8):1833-1841. PubMed ID: 34379571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
